File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers

TitleGenome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
Authors
KeywordsOvarian cancer
Methylome profiling
Epigenetic
Demethylating agents
Tumor grading
Issue Date2021
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.clinicalepigeneticsjournal.com
Citation
Clinical Epigenetics, 2021, v. 13, p. article no. 142 How to Cite?
AbstractBackground: In contrast to stable genetic events, epigenetic changes are highly plastic and play crucial roles in tumor evolution and development. Epithelial ovarian cancer (EOC) is a highly heterogeneous disease that is generally associated with poor prognosis and treatment failure. Profiling epigenome-wide DNA methylation status is therefore essential to better characterize the impact of epigenetic alterations on the heterogeneity of EOC. Methods: An epigenome-wide association study was conducted to evaluate global DNA methylation in a retrospective cohort of 80 mixed subtypes of primary ovarian cancers and 30 patients with high-grade serous ovarian carcinoma (HGSOC). Three demethylating agents, azacytidine, decitabine, and thioguanine, were tested their anti-cancer and anti-chemoresistant effects on HGSOC cells. Results: Global DNA hypermethylation was significantly associated with high-grade tumors, platinum resistance, and poor prognosis. We determined that 9313 differentially methylated probes (DMPs) were enriched in their relative gene regions of 4938 genes involved in small GTPases and were significantly correlated with the PI3K-AKT, MAPK, RAS, and WNT oncogenic pathways. On the other hand, global DNA hypermethylation was preferentially associated with recurrent HGSOC. A total of 2969 DMPs corresponding to 1471 genes were involved in olfactory transduction, and calcium and cAMP signaling. Co-treatment with demethylating agents showed significant growth retardation in ovarian cancer cells through differential inductions, such as cell apoptosis by azacytidine or G2/M cell cycle arrest by decitabine and thioguanine. Notably, azacytidine and decitabine, though not thioguanine, synergistically enhanced cisplatin-mediated cytotoxicity in HGSOC cells. Conclusions: This study demonstrates the significant association of global hypermethylation with poor prognosis and drug resistance in high-grade EOC and highlights the potential of demethylating agents in cancer treatment.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/304332
ISSN
2023 Impact Factor: 4.8
2023 SCImago Journal Rankings: 1.727
PubMed Central ID
ISI Accession Number ID
Errata

 

DC FieldValueLanguage
dc.contributor.authorChan, DW-
dc.contributor.authorLam, WY-
dc.contributor.authorChen, F-
dc.contributor.authorYung, MMH-
dc.contributor.authorChan, YS-
dc.contributor.authorChan, WS-
dc.contributor.authorHe, F-
dc.contributor.authorLiu, S-
dc.contributor.authorChan, KKL-
dc.contributor.authorLi, B-
dc.contributor.authorNgan, HYS-
dc.date.accessioned2021-09-23T08:58:34Z-
dc.date.available2021-09-23T08:58:34Z-
dc.date.issued2021-
dc.identifier.citationClinical Epigenetics, 2021, v. 13, p. article no. 142-
dc.identifier.issn1868-7075-
dc.identifier.urihttp://hdl.handle.net/10722/304332-
dc.descriptionHybrid open access-
dc.description.abstractBackground: In contrast to stable genetic events, epigenetic changes are highly plastic and play crucial roles in tumor evolution and development. Epithelial ovarian cancer (EOC) is a highly heterogeneous disease that is generally associated with poor prognosis and treatment failure. Profiling epigenome-wide DNA methylation status is therefore essential to better characterize the impact of epigenetic alterations on the heterogeneity of EOC. Methods: An epigenome-wide association study was conducted to evaluate global DNA methylation in a retrospective cohort of 80 mixed subtypes of primary ovarian cancers and 30 patients with high-grade serous ovarian carcinoma (HGSOC). Three demethylating agents, azacytidine, decitabine, and thioguanine, were tested their anti-cancer and anti-chemoresistant effects on HGSOC cells. Results: Global DNA hypermethylation was significantly associated with high-grade tumors, platinum resistance, and poor prognosis. We determined that 9313 differentially methylated probes (DMPs) were enriched in their relative gene regions of 4938 genes involved in small GTPases and were significantly correlated with the PI3K-AKT, MAPK, RAS, and WNT oncogenic pathways. On the other hand, global DNA hypermethylation was preferentially associated with recurrent HGSOC. A total of 2969 DMPs corresponding to 1471 genes were involved in olfactory transduction, and calcium and cAMP signaling. Co-treatment with demethylating agents showed significant growth retardation in ovarian cancer cells through differential inductions, such as cell apoptosis by azacytidine or G2/M cell cycle arrest by decitabine and thioguanine. Notably, azacytidine and decitabine, though not thioguanine, synergistically enhanced cisplatin-mediated cytotoxicity in HGSOC cells. Conclusions: This study demonstrates the significant association of global hypermethylation with poor prognosis and drug resistance in high-grade EOC and highlights the potential of demethylating agents in cancer treatment.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.clinicalepigeneticsjournal.com-
dc.relation.ispartofClinical Epigenetics-
dc.rightsClinical Epigenetics. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectOvarian cancer-
dc.subjectMethylome profiling-
dc.subjectEpigenetic-
dc.subjectDemethylating agents-
dc.subjectTumor grading-
dc.titleGenome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers-
dc.typeArticle-
dc.identifier.emailChan, DW: dwchan@HKUCC-COM.hku.hk-
dc.identifier.emailYung, MMH: mhyung@hku.hk-
dc.identifier.emailChan, WS: waisun10@hku.hk-
dc.identifier.emailHe, F: hff1314@HKUCC-COM.hku.hk-
dc.identifier.emailLiu, S: stephasl@hku.hk-
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hk-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityChan, DW=rp00543-
dc.identifier.authorityLiu, S=rp00372-
dc.identifier.authorityChan, KKL=rp00499-
dc.identifier.authorityNgan, HYS=rp00346-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s13148-021-01130-5-
dc.identifier.pmid34294135-
dc.identifier.pmcidPMC8296615-
dc.identifier.scopuseid_2-s2.0-85111142560-
dc.identifier.hkuros325608-
dc.identifier.volume13-
dc.identifier.spagearticle no. 142-
dc.identifier.epagearticle no. 142-
dc.identifier.isiWOS:000680086800001-
dc.publisher.placeUnited Kingdom-
dc.relation.erratumdoi:10.1186/s13148-021-01141-2-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats